Switzerland's drug regulator has approved the first malaria treatment for newborns, developed by Novartis, to combat malaria in Africa. The drug, Coartem Baby, is safe for infants under five kilograms and aims to protect them from malaria, which kills many children under five. Eight African countries are expected to approve the medicine soon, with a not-for-profit rollout planned. Teljes cikk (Euronews.com)